Syndivia is a finalist of OneStart 2015

LONDON, UK, April 15, 2015 – Syndivia is among the 10 finalists of OneStart Europe, out of an initial 650 applications from 50 countries. Dedicated mentors from Johnson & Johnson Innovation, Takeda Ventures, Bristol-Myers Squibb, GSK, Roche, AstraZeneca, McKinsey & Company, MedCity, Silicon Valley Bank, Forresters and Olswang have highly rated Syndivia's C&R linker technology and its potential to enable an ADC approach for non-internalizing targets in oncology.

OneStart is the world’s largest life sciences and health care startup accelerator programme organized by SR One (the corporate venture capital arm of GlaxoSmithKline) and Oxbridge Biotech Roundtable. It welcomes ideas from across the spectrum: therapeutics, diagnostics, software, devices and research tools.

(More details: